A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 282,900 shares of ALDX stock, worth $1.55 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
282,900
Previous 374,900 24.54%
Holding current value
$1.55 Million
Previous $1.23 Million 23.59%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$3.25 - $4.72 $299,000 - $434,240
-92,000 Reduced 24.54%
282,900 $936,000
Q1 2024

May 15, 2024

BUY
$2.77 - $4.22 $65,095 - $99,170
23,500 Added 6.69%
374,900 $1.23 Million
Q4 2023

Feb 14, 2024

SELL
$1.47 - $6.06 $102,165 - $421,170
-69,500 Reduced 16.51%
351,400 $1.23 Million
Q3 2023

Nov 14, 2023

SELL
$6.11 - $8.16 $80,041 - $106,896
-13,100 Reduced 3.02%
420,900 $2.81 Million
Q2 2023

Aug 14, 2023

SELL
$7.11 - $11.89 $667,629 - $1.12 Million
-93,900 Reduced 17.79%
434,000 $3.64 Million
Q1 2023

May 15, 2023

SELL
$5.77 - $9.93 $358,894 - $617,646
-62,200 Reduced 10.54%
527,900 $5.24 Million
Q4 2022

Feb 14, 2023

SELL
$5.08 - $7.09 $1.56 Million - $2.18 Million
-307,500 Reduced 34.26%
590,100 $4.11 Million
Q3 2022

Nov 14, 2022

BUY
$3.8 - $7.74 $40,280 - $82,044
10,600 Added 1.2%
897,600 $4.79 Million
Q2 2022

Aug 15, 2022

BUY
$2.43 - $4.85 $921,699 - $1.84 Million
379,300 Added 74.71%
887,000 $3.54 Million
Q1 2022

May 16, 2022

SELL
$3.25 - $5.17 $589,875 - $938,355
-181,500 Reduced 26.33%
507,700 $2.26 Million
Q4 2021

Feb 14, 2022

SELL
$3.5 - $9.63 $347,200 - $955,296
-99,200 Reduced 12.58%
689,200 $2.76 Million
Q3 2021

Nov 15, 2021

SELL
$7.94 - $11.31 $1.8 Million - $2.57 Million
-227,100 Reduced 22.36%
788,400 $6.92 Million
Q2 2021

Aug 16, 2021

BUY
$10.44 - $14.85 $1.88 Million - $2.67 Million
180,100 Added 21.56%
1,015,500 $11.5 Million
Q1 2021

May 17, 2021

BUY
$6.53 - $14.42 $1.06 Million - $2.34 Million
162,100 Added 24.08%
835,400 $9.93 Million
Q4 2020

Feb 16, 2021

BUY
$6.31 - $8.13 $458,737 - $591,051
72,700 Added 12.1%
673,300 $4.62 Million
Q3 2020

Nov 16, 2020

BUY
$4.0 - $7.53 $2.09 Million - $3.94 Million
523,600 Added 680.0%
600,600 $4.45 Million
Q2 2020

Aug 14, 2020

BUY
$1.97 - $5.05 $84,119 - $215,635
42,700 Added 124.49%
77,000 $321,000
Q1 2020

May 15, 2020

BUY
$1.62 - $6.4 $39,204 - $154,880
24,200 Added 239.6%
34,300 $85,000
Q4 2019

Feb 14, 2020

BUY
$4.73 - $7.98 $47,773 - $80,598
10,100 New
10,100 $59,000

Others Institutions Holding ALDX

About Aldeyra Therapeutics, Inc.


  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $320M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.